hiroshi uchino

Dr. hiroshi uchino

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2017 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
FSFumika Shigiyama
Fumika Shigiyama
NKNaoki Kumashiro
Naoki Kumashiro
MMMasahiko Miyagi
Masahiko Miyagi
KIKayoko Ikehara
Kayoko Ikehara
EKEiichiro Kanda
Eiichiro Kanda
THTakahisa Hirose
Takahisa Hirose
Background: Recent studies reported that sodium glucose cotransporter 2 (SGLT2) inhibitors can potentially reduce the risk of cardiovascular mortality in patients with type 2 diabetes mellitus (T2DM). However, there is little or no information on the therapeutic effects of SGLT2 inhibitors on the progression of atherosclerosis. This dapagliflozin effectiveness on vascular endothelial function and glycemic control (DEFENCE) study was designed to determine the effects of dapagliflozin, a SGLT2 inhibitor, on endothelial function in patients with early-stage T2DM. Methods: DEFENCE is a prospective, randomized, open-label, blinded-endpoint, parallel-group, comparative clinical trial. Between October 2015 and August 2016, 80 T2DM patients treated with 750 mg of metformin (hemoglobin A1c ≥6.0 and 7.0% showed significant improvement of FMD in the dapagliflozin group than metformin group (P < 0.05). HbA1c, fasting plasma glucose, plasma glucagon, and body weight significantly decreased in both groups. Interestingly, urine 8-hydroxy-2′-deoxyguanosin, a biomarker of oxidative stress, was significantly lower in the dapagliflozin group than metformin group at 16 weeks (P < 0.001). Conclusions: Dapagliflozin add-on therapy to metformin for 16 weeks improved endothelial function, as assessed by FMD, in patients with inadequately controlled early-stage T2DM. Improvement in oxidative stress may contribute to the improvement in FMD. Trial registration University Hospital Medical Information Network Clinical Trial Registry (UMIN000018754)

1 January 2008 in Hypertension Research
Verified
Journal Article
Closed access
PDF file
SNShiho Nakayama
Shiho Nakayama
HWHirotaka Watada
Hirotaka Watada
TMTomoya Mita
Tomoya Mita
FIFuki Ikeda
Fuki Ikeda
TSTomoaki Shimizu
Tomoaki Shimizu
RKRyuzo Kawamori
Ryuzo Kawamori
Angiotensin II type-1 receptor blockers (ARBs) are regarded as first-line treatments for type-2 diabetes with hypertension. Despite the availability of various types of ARBs, there are no comparative studies of their effects on patients with diabetes. In this open-label prospective crossover study, we compared the effects of olmesartan (20 mg/day) and telmisartan (40 mg/day). Twenty Japanese early-stage type-2 diabetes patients with hypertension treated with valsartan (80 mg/day) for at least 8 weeks were recruited to this study. At study entry, valsartan was changed to olmesartan (20 mg/day) or telmisartan (40 mg/day) and administered for 8 weeks. The drugs were then switched and treatment was continued for another 8 weeks. We analyzed the blood pressure lowering effects of each drug by 24-h ambulatory blood pressure monitoring at 0, 8, and 16 weeks. Simultaneously, we measured metabolic parameters and inflammation markers. Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did telmisartan. While there were no differences between the groups in metabolic parameters, including HbA1c and adiponectin, the decreases in serum interleukin-6 and highly sensitive C-reactive protein were more significant by olmesartan treatment. Our results indicate that olmesartan has more potent arterial blood pressure lowering and anti-inflammatory effects than telmisartan. (Hypertens Res 2008; 31: 7−13)

25 May 2017 in Diabetes Therapy
Verified
Journal Article
Open access
PDF file
RIRyo Iga
Ryo Iga
HUhiroshi uchino
hiroshi uchino
KKKen Kanazawa
Ken Kanazawa
SUShuki Usui
Shuki Usui
MMMasahiko Miyagi
Masahiko Miyagi
THTakahisa Hirose
Takahisa Hirose
Introduction Optimal adjustment of basal insulin to overcome hypoglycemia and glycemic variability (GV) depends on its duration of action and peak-less profile. Owing to the ability of long-acting basal insulin to avoid hypoglycemia, we titrated pre-meal glucose to normal fasting blood glucose, 80–110 mg/dL (4.5–6.1 mmol/L), and post-meal glucose to 80–140 mg/dL (4.5–7.8 mmol/L). The purpose of this study was to evaluate two basal insulin analogues degludec (IDeg) and glargine (IGlar), injected in the morning, for GV using continuous glucose monitoring (CGM) in type 1 diabetes (T1DM). Methods In this crossover study, 20 Japanese patients with T1DM (age 54 ± 16 years, disease duration 16 ± 8 years, BMI 24 ± 4 kg/m2, HbA1c 7.4 ± 0.8%) were randomized into one of two different starting regimens, and CGM was conducted on three consecutive days during the last week of each 12-week titration period. Treatment satisfaction was assessed at the end of each treatment period using the Diabetes Therapy-Related Quality of Life Questionnaire (DTR-QOL). Results There were no differences in HbA1c, total insulin dosage, body weight changes, and basal to bolus ratio between the IDeg and IGlar arms. The day-to-day variability in fasting interstitial GV on the CGM curves was significantly less in the IDeg than IGlar treatment period (25.9 ± 22.0 vs. 43.8 ± 30.1 mg/dl, p = 0.04). Other markers of GV, calculated by the EasyGV software, including mean amplitude of glycemic excursions (MAGE), J-index, total and nocturnal hypoglycemia were not different between the two treatment periods. The score of “satisfaction with treatment”, a subdomain of the DTR-QOL system, was higher in the IDeg period. Conclusion Thus, the morning injection of the two long-acting insulin analogues seemed similar with regard to the magnitude of hypoglycemia in T1DM, but treatment with IDeg was associated with lower day-to-day variation in glucose level. These results suggest that IDeg is safe with minimal morning GV in patients with T1DM. Clinical trial registration Japanese Clinical Trials Registry, UMIN000012358.

1 February 2015 in Metabolism
Verified
Journal Article
Closed access
SPSandra Pereira
Sandra Pereira
DBDanna M. Breen
Danna M. Breen
ANAnthony E. Naassan
Anthony E. Naassan
PWPenny Y.T. Wang
Penny Y.T. Wang
HUhiroshi uchino
hiroshi uchino
Adria GiaccaAdria Giacca
Adria Giacca

1 January 2006 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
TMTomoya Mita
Tomoya Mita
HWHirotaka Watada
Hirotaka Watada
HUhiroshi uchino
hiroshi uchino
TSTomoaki Shimizu
Tomoaki Shimizu
THTakahisa Hirose
Takahisa Hirose
RKRyuzo Kawamori
Ryuzo Kawamori
The aim of this study was to assess the association between high sensitivity-C-reactive protein (hs-CRP), a sensitive marker of inflammation, and early-stage carotid atherosclerosis, in patients with early-state type 2 diabetes mellitus. The study subjects were 75 patients with type 2 diabetes mellitus without obvious diabetic vascular complications, who were not on any medication, and whose HbA1c level was less than 6.5%. We evaluated the mean intima-media thickness (IMT) of the common carotid artery (CCA) by ultrasound B-mode imaging. Then, we investigated various factors associated with CCA-IMT including hs-CRP. Serum hs-CRP levels correlated well with factors strongly associated with insulin resistance such as homeostasis model assessment of insulin resistance (HOMA-IR), fasting insulin level, and body mass index. Serum hs-CRP also correlated with mean CCA-IMT and serum levels of soluble intercellular adhesion molecule-1. Multivariate regression analysis using mean CCA-IMT as the dependent variable identified only age, hs-CRP, and diastolic blood pressure as independent determinants of mean CCA-IMT. While hs-CRP associates with insulin resistance and subclinical atherosclerosis in ealy-state type 2 diabetes, our data suggest that hs-CRP is a useful marker of subclinical atherosclerosis in early-state type 2 diabetes mellitus independent of factors that directly reflect insulin resistance.

1 January 2006 in Endocrine Journal
Verified
Journal Article
Open access
PDF file
TYTomoaki Yoshihara
Tomoaki Yoshihara
NKNaoki Kumashiro
Naoki Kumashiro
YKYoshie Kanazawa
Yoshie Kanazawa
TMTomoya Mita
Tomoya Mita
YSYuko Sakurai
Yuko Sakurai
THTakahisa Hirose
Takahisa Hirose
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies